MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer

At our institution, all patients receiving external beam and/or brachytherapy as part of the
treatment of primary cervical cancer receive CT, PET, and MRI simulation scans as standard
of care. Brachytherapy patients also receive weekly T1/T2 weighted MR simulation scans as
part of their treatment planning.

We propose the use of additional MR sequences to the standard T1/T2 weighted MR simulation
scans. The data obtained from these additional sequences will be used for improving tumor
delineation and obtaining prognostic information.

Inclusion Criteria:

- Patients must have biopsy-proven newly diagnosed squamous cell cervical cancer (FIGO
clinical stages IB2-IVA).

- Patients must be ≥ 18 years of age.

- Patients must be able to receive standard radiation therapy (external beam radiation
and brachytherapy) with or without chemotherapy.

- Patients with distant metastatic disease are eligible provided the estimated survival
of the patient is at least one year.

- Patients must be scheduled to undergo or have already undergone FDG-PET/CT imaging
for clinical staging cervical cancer at Barnes-Jewish Hospital Clinical PET facility
on the Siemens Biograph 40 True Point Tomograph Scanner or elsewhere in the WUSM
Nuclear Medicine department using the quality controls instituted by Nuclear
Medicine.

- Patients must be able to give informed consent.

Exclusion Criteria:

- Patients with another known active malignancy.

- Patients who have received treatment for any malignancy (with the exception of
non-melanoma skin cancer) in the past 5 years.

- Pregnant or breastfeeding patients.

- Patients whose tumors are not FDG avid on baseline standard of care FDG-PET/CT
imaging.

- Patients with contraindications to MRI scanning.